Examining the relationship between cancer invasion/metastasis and drug resistance

Current Cancer Drug Targets

Volumn 2, Issue 3, 2002, Pages 257-277

  Liang, Y ^a   McDonnell, S ^a   Clynes, M ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; AZACITIDINE; CARBOPLATIN; CISPLATIN; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; HYDROXYUREA; MELPHALAN; METHOTREXATE; MEVINOLIN; MITOXANTRONE; PACLITAXEL; SPARFOSIC ACID; TENIPOSIDE; THIOTEPA; UFT; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BASEMENT MEMBRANE; CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; DRUG TRANSPORT; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; METASTASIS; NONHUMAN; PHENOTYPE; REVIEW; TUMOR CELL;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE;

EID: 0036342838     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023333872     Document Type: Review

References (234)

1. The implication of angiogenesis for the biology and therapy of cancer metastasis
2. Degradation of basement membrane by murine tumor cells
3. Production of metastases by treatment with carcinostatic agents. Effects of carcinostatic agents on the host
4. Facilitation of tumour progression by cancer therapy
5. Modification of the metastatic potential of tumor cells by drugs
6. Can cancer chemotherapy enhance the malignant behaviour of tumours?
7. Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes?
8. The effect of local roentgen irradiation on the biological behavior of a transplantable mouse carcinoma. Increased frequency of pulmonary metastasis
9. Enhancement of pulmonary metastasis by X-irradiation in rats bearing mammary cancer
10. Examination for a correlation between probability of development of distant metastasis and of local recurrence
11. Influence of pre-irradiation of lung on development of artificial pulmonary metastases of fibrosarcoma in mice
12. The effect of lung irradiation on the incidence of pulmonary metastasis in mice
13. Artificial metastases and decrease of fibrinolysis in the nude mouse lung after hemithoracic irradiation
14. Radiation enhancement of metastasis: A review
15. Radiation therapy to a primary tumor accelerates metastatic growth in mice
16. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants
17. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells
18. Multidrug resistance and its circumvention
19. Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis
20. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer
21. Expression of a multidrug resistance gene in human cancers
22. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
23. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinoma
24. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
25. Biology of the multidrug resistance-associated protein, MRP
26. Sequential coexpresion of the multidrug resistance genes mrp and mdr-1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells
27. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines
28. The MRP gene encodes an ATP-dependent export carrier for leukotriene C4 and structurally related conjugates
29. Selection with melphalan or paclitaxel (taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness
30. The ultrastructural composition of basement membranes in vivo
31. Cell adhesion: The molecular basis of tissue architecture and morphogenesis
32. Extracellular matrix and growth factors: An integrated interplay controlling tissue repair and progression to disease
33. Basement membranes complexes with biological activity
34. Comparison of tumour cell invasion assay: Human amnion versus reconstituted basement membrane barriers
35. A rapid in vitro assay for quantitating the invasive potential of tumor cells
36. Supernatants of acquired immunodeficiency syndrom-related Kaposi's sarcoma cells induce endothelial cell chemotaxis and invasiveness
37. Molecular insights into cancer invasion: Strategies for prevention and intervention
38. Life at the leading edge: The formation of cell protrusions
39. Cytokine-induced pseudopodial protrusion is coupled to tumor cell migration
40. Proteinases and inhibitors
41. th Jan Waldenstrom Lecture. The biology of human cancer metastasis
42. General mechanisms of metastasis
43. Angiogenesis
44. The distribution of secondary growths in cancer of the breast
45. Metastasis results from pre-existing variant cells within a malignant tumor
46. Evidence for the clonal origin of spontaneous metastasis
47. Ras-responsive genes and tumour metastasis
48. The potential roles of nm23 in cancer metastasis and cellular differentiation
49. KA11, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
50. Kiss-1, a novel human malignant melanoma metastasis-suppressor gene
51. Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection
52. Enhancement by cytotoxic agents of artificial pulmonary metastasis
53. The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastasis in mice
54. Metastasis of a transplantable mammary tumour in rats treated with cyclophosphamide and/or irradiation
55. Enhancement of artificial lung metastases in mice caused by cyclophosphamide. 1. Participation of impairment of host anti-tumor resistance
56. Enhancement of B16 melanoma pulmonary colonization in mice following bleomycin or hyperoxia
57. Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury
58. Amplified pulmonary metastases of a rat rhabdomyosarcoma in response to nitrosourea treatment
59. The metastatic function of cancer cells as revealed by a rat sarcoma model
60. In vivo emergence of a highly metastatic tumour cell line from a rat rhabdomyosarcoma after treatment with an alkylating agent
61. Oncogene and MDR1 gene expression in rat rhabdomyosarcoma sublines of different metastatic potential
62. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay
63. Enhancement of experimental metastasis by pre-treatment of tumour cells with hydroxyurea
64. Enhanced experimental metastatic capacity of a murine melanoma following a pre-treatment with anticancer drugs
65. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
66. Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice
67. Single treatment with cisplatin or UFT, but not their combination treatment enhances the metastatic capacity of mouse fibrosarcoma cells
68. Invasive properties of cadmium-resistant human fibrosarcoma HT-1080 cells
69. Characterization of cysteine proteases and their endogenous inhibitors in MCF-7 and adriamycin-resistant MCF-7 human breast cancer cells
70. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance
71. Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in matrigel-based in vitro assays
72. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966
73. Metastatic potential and multidrug resistance correlation in the B16 melanoma system
74. Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis
75. Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1
76. Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin b
77. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents
78. Alteration of metastatic potential of ovarian cancer in clinical course
79. Hydroxyurea and radiotherapy in head and neck cancer
80. The incidence of metastases after multimodal therapy for cancer of the head and neck
81. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis
82. P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients
83. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary invasion at the time of rescue mastectomy after induction chemotherapy
84. Redefining the target: Chemotherapeutics as antiangiogenics
85. Selective chemotherapy in relation to the site of tumor transplantation
86. The influence of site of metastasis on tumour growth and response to chemotherapy
87. Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases
88. Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastasis, and between different metastasis in the human tumor colony-forming assay
89. Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin
90. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil
91. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay
92. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells
93. Fibroblast growth factors an epigenetic mechanism of broad spectrum resistance to anticancer drugs
94. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells
95. Hepatocyte growth factor decreases sensitivity to chemotherapeutic agents and stimulates cell adhesion, invasion, and migration
96. Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells
97. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines
98. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability
99. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique
100. P-glycoprotein expression during tumor progression in the rat liver
101. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53
102. Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro
103. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents
104. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
105. Modulation of activity of the promoter of the human MDR1 gene by ras and p53
106. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53
107. MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases
108. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53
109. Evidence for a novel gene associated with low tumor metastatic potential
110. Molecular cloning and functional expression of the second mouse nm23/NDP kinase gene, nm23-M2
111. Reduced Nm23/AWD protein in tumour metastasis and aberrant drosophila development
112. Identification of a second human nm23 Gene, nm23-H2
113. Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells
114. Nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localized on chromosome 16p13
115. The human Nm23/nucleoside diphosphate kinases
116. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells
117. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization and enzymatic activity
118. Inhibition of cell motility after nm23 transfection of human and murine tumor cells
119. Immunohistochemical analysis of expression of nm23H1/nucleoside diphosphate kinase in human thyroid carcinomas: Lack of correlation between its expression and lymph node metastasis
120. Phosphorylation of ATP-citrate lyase by nucleoside diphosphate kinase
121. Site-directed Mutation of nm23-H1. Mutations lacking motility suppressive capacity upon transfection are deficient in histidine-dependent protein phosphotransferase pathways in vitro
122. A serine phosphorylation of nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential
123. Human c-myc transcription factor PuF identified as nm23-h2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis
124. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines
125. Nm23 in ovarian cancer: Correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters
126. Identification of compounds with preferential inhibitory activity against Low-Nm23-expressing human breast carcinoma and melanoma cell lines
127. The nm23-H1 gene as a predictor of sensitivity to chemothera-peutic agents in oesophageal squamous cell carcinoma
128. Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas
129. Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials
130. Transformation of rat liver epithelial cells with v-Ha-ras or v-raf causes expression of MDR-1, gluthathione-S-transferase-P and increased resistance to cytotoxic chemicals
131. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin
132. Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-Ha-ras genes
133. Augmented expression of normal c-myc is sufficient for cotransformation of rat embryo cells with a mutant ras gene
134. Modulation of Cis-platinum resistance in friend erythroleukemia cells by c-myc
135. Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma
136. Bcl-2 and the regulation of programmed cell death
137. Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways
138. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases
139. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance
140. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line
141. Tumor hypoxia, drug resistance and metastases
142. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling
143. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cipl, which inhibits p34Cdc2 kinase
144. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene
145. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs
146. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
147. Role of erbB2 in breast cancer chemosensitivity
148. DNA repair relationship to drug and radiation resistance, metastasis and growth factors
149. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms
150. General consideration for studies of experimental cancer metastasis
151. Enhanced metastatic potential of murine fibrosarcoma treated in vitro with ultraviolet radiation
152. Dynamic heterogeneity: Rapid generation of metastatic variants in mouse B16 melanoma cells
153. Comparison of spontaneous mutation rates of normal and chemically transformed human skin fibroblasts
154. Correlation of frequency of induced mutation and metastatic potential in tumor cell lines from a single mouse mammary tumor
155. Metastatic potential and spontaneous mutation rates: Studies with two murine cell lines and their recently induced metastatic variants
156. Drug sensitivity and metastatic ability in B16 melanoma cells
157. Patterns of DNA methylation and gene expression in human tumor cell lines
158. Drug induced hypermethylation of DNA sequences within mammalian cells
159. Urokinase-type plasminogen activator and malignancy
160. Emerging roles for proteinases in cancer
161. The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis
162. Matrix metalloproteinases
163. Molecular and cellular biology of intermediate filaments
164. The intermediate-filament proteins vimentin and desmin are phosphorylated in specific domains
165. Vimentin serves as a phosphate sink during the apparent activation of protein kinases by okadaic acid in mammalian cells
166. Expression of cytokeratin confers multiple drug resistance
167. Oncogenic regulation and function of keratin 8 and 18
168. Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents
169. Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line
170. Role of intermediate filaments in migration, invasion and metastasis
171. Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and metastatic potential
172. Disruption of normal cytokeratin formation, by the transfection of a delected cDNA into a highly metastatic melanoma cell line decreases the invasive potential
173. Differential expression of intermediate filament proteins in metastatic and nonmetastatic variants of the BSP 73 tumor
174. Coexpression of keratin- and vimentin-type intermediate filaments in human metastatic carcinoma cells
175. Differential expression of intermediate-filament proteins in murine sarcoma 180 ascites or solid tumor
176. Differential expression of intermediate filament proteins in two rat ascites hepatoma lines of common origin
177. Molecular portraits of human breast tumours
178. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
179. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells
180. Integrin signaling
181. 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line
182. Altered expression of integrins in adriamycin-resistant human breast cancer cells
183. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
184. Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs
185. Localization of specificity determining sites in cadherin cell adhesion molecules
186. KiP1 on resistance of tumor cells to anticancer agents
187. Cell adhesion and drug resistance in cancer
188. Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes
189. FAK): A point of convergence in the action of neuropeptides, integrins, and oncogenes
190. Role of focal adhesion kinase in integrin signaling
191. Disruption of epithelial cell-matrix interactions induces apoptosis
192. Inhibition of pp125FAK in cultured fibroblasts results in apoptosis
193. Cleavage of focal adhesion kinase by caspases during apoptosis
194. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties
195. Role of galectin-3 in adenocarcinoma liver metastasis
196. Involvement of galectin-3 expression in colorectal cancer progression and metastasis
197. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer
198. Cyclooxygenase in biology and disease
199. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
200. Colorectal cancer and nonsteroidal anti-inflammatory drugs
201. Expression of cyclooxygenase-2 in human lung carcinoma
202. Expression of cyclooxygenase-2 in human gastric carcinoma
203. Cyclooxygenase expression is up-regulated in human pancreatic cancer
204. Expression of cyclooxygenase-2 in hepatocellular carcinoma: Relevance to tumor dedifferentiation
205. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
206. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
207. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
208. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxynase-2
209. Inhibition of cyclooxygenase gene expression by p53
210. Inhibition of NF-kappa B by sodium salicylate and aspirin
211. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1 luciferase transgenic mice
212. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer
213. Nitric oxide synthases: Roles, tolls and controls
214. Nitric Oxide: Physiology, pathophysiology, and pharmacology
215. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase
216. 6-methylguanine-DNA-methyltransferase
217. Nitric oxide enhancement of melphalan-induced cytotoxicity
218. Nitric oxide and some NO donor compounds enhance the cytotoxicity of cisplatin
219. Evidence that nitric oxide enhances cadmium toxicity by display the metals from metallothionein
220. Role of natural killer cells in the destruction of circulating tumor emboli
221. Role of natural killer cells in tumor growth and metastasis: C57 BL/6 normal and beige mice
222. Role of natural killer cells in the control of metastatic spread and growth of tumor cells in mice
223. Effect of chemotherapy on natural killer activity and antibody-dependent cell mediated cytotoxicity in carcinoma of the lung
224. Enhancement of pulmonary metastases induced by decreased lung natural killer cell activity
225. Effect of chemotherapeutic agents on natural killer cell-mediated cytotoxicity in mice
226. Ovarian reticular cell sarcoma of the louse (M5076) made resistant to cyclophosphamide
227. Metastatic behavior of an adriamycin-resistant murine tumor
228. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 Mouse melanoma cells
229. Down-regulation of ras and myc expression associated with mdr-1 overexpression in adriamycin-resistant tumor cells